Literature DB >> 10749360

Cardiac electrophysiology in genetically engineered mice.

J Gehrmann1, C I Berul.   

Abstract

The mouse has become the principal animal model for studying biologic processes in mammals. Major advances in transgene and gene targeting technology enabled manipulation of the mouse genome in a predictable fashion. Mutant mouse strains provide important insights into the molecular mechanisms underlying normal and disordered cardiac conduction and sudden cardiac death. A variety of mouse strains harboring gene mutations leading to inherited developmental disorders have been designed. Structural protein abnormalities, connexin protein defects, and ion channelopathies associated with human clinical phenotypes, including congenital heart disease, cardiomyopathies, long QT syndrome, and muscular dystrophy, have been engineered into the mouse genome, creating models of human electrophysiologic disease. Functional analyses of the underlying molecular mechanisms of resultant phenotypes require appropriate and sophisticated experimental methodology. In this review, genetic mouse models pertinent to human arrhythmogenic disorders and their application to present-day ex vivo and in vivo murine electrophysiologic technology at the whole organ and animal levels are discussed.

Entities:  

Mesh:

Year:  2000        PMID: 10749360     DOI: 10.1111/j.1540-8167.2000.tb01806.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  14 in total

1.  Pitx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm.

Authors:  Rangarajan D Nadadur; Michael T Broman; Bastiaan Boukens; Stefan R Mazurek; Xinan Yang; Malou van den Boogaard; Jenna Bekeny; Margaret Gadek; Tarsha Ward; Min Zhang; Yun Qiao; James F Martin; Christine E Seidman; Jon Seidman; Vincent Christoffels; Igor R Efimov; Elizabeth M McNally; Christopher R Weber; Ivan P Moskowitz
Journal:  Sci Transl Med       Date:  2016-08-31       Impact factor: 17.956

2.  In-vivo electrophysiological study in mice with chronic anterior myocardial infarction.

Authors:  Thomas Korte; Martin Fuchs; Zeynep Guener; Joachim v Bonin; Marcos de Sousa; Michael Niehaus; Jürgen Tebbenjohanns; Helmut Drexler
Journal:  J Interv Card Electrophysiol       Date:  2002-06       Impact factor: 1.900

3.  Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein.

Authors:  H Kasahara; H Wakimoto; M Liu; C T Maguire; K L Converso; T Shioi; W Y Huang; W J Manning; D Paul; J Lawitts; C I Berul; S Izumo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

4.  The ECG in cardiovascular-relevant animal models of electrophysiology.

Authors:  Sven Kaese; Gerrit Frommeyer; Sander Verheule; Gunther van Loon; Josef Gehrmann; Günter Breithardt; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-06-06

5.  Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.

Authors:  Ronny Alcalai; Hiroko Wakimoto; Michael Arad; David Planer; Tetsuo Konno; Libin Wang; Jon G Seidman; Christine E Seidman; Charles I Berul
Journal:  J Cardiovasc Electrophysiol       Date:  2010-08-30

6.  Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model.

Authors:  Amir Toib; Chen Zhang; Giulia Borghetti; Xiaoxiao Zhang; Markus Wallner; Yijun Yang; Constantine D Troupes; Hajime Kubo; Thomas E Sharp; Eric Feldsott; Remus M Berretta; Neil Zalavadia; Danielle M Trappanese; Shavonn Harper; Polina Gross; Xiongwen Chen; Sadia Mohsin; Steven R Houser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-23       Impact factor: 4.733

7.  Determinants of cardiac electrophysiological properties in mice.

Authors:  Gregory O Appleton; Yi Li; George E Taffet; Craig J Hartley; Lloyd H Michael; Mark L Entman; Robert Roberts; Dirar S Khoury
Journal:  J Interv Card Electrophysiol       Date:  2004-08       Impact factor: 1.900

8.  NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function.

Authors:  Koichiro Kuwahara; Yoshihiko Saito; Makoto Takano; Yuji Arai; Shinji Yasuno; Yasuaki Nakagawa; Nobuki Takahashi; Yuichiro Adachi; Genzo Takemura; Minoru Horie; Yoshihiro Miyamoto; Takayuki Morisaki; Shinobu Kuratomi; Akinori Noma; Hisayoshi Fujiwara; Yasunao Yoshimasa; Hideyuki Kinoshita; Rika Kawakami; Ichiro Kishimoto; Michio Nakanishi; Satoru Usami; Yoshitomo Saito; Masaki Harada; Kazuwa Nakao
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

9.  Angiotensin II type 1a receptor signalling directly contributes to the increased arrhythmogenicity in cardiac hypertrophy.

Authors:  Shinji Yasuno; Koichiro Kuwahara; Hideyuki Kinoshita; Chinatsu Yamada; Yasuaki Nakagawa; Satoru Usami; Yoshihiro Kuwabara; Kenji Ueshima; Masaki Harada; Toshio Nishikimi; Kazuwa Nakao
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.

Authors:  Lei Song; Ronny Alcalai; Michael Arad; Cordula M Wolf; Okan Toka; David A Conner; Charles I Berul; Michael Eldar; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.